European Journal of Dermatology


Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study Volume 33, issue 6, November-December 2023


  • Figure 1.
Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Japan

Atopic dermatitis (AD) is a chronic skin condition with severe pruritus, type 2 inflammation, and an impaired skin barrier, notably impacting quality of life [1]. Recent AD treatment advances include biologics such as ­nemolizumab, which targets interleukin-31 receptor alpha (IL-31RA), a key factor in pruritus associated with AD. [2, 3]. In Japan, nemolizumab is authorized for the ­treatment of pruritus associated with AD. The criteria for this prescription include patients who have [...]

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License